ZKN013 / Eloxx Pharma, Almirall - LARVOL DELTA

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates (GlobeNewswire) - "Eloxx Pharmaceuticals, Inc...provided program updates for ELX-02 and ZKN-013, including Orphan Drug Designation (ODD) for ELX-02....Initiated Phase 1 Single Ascending Dose (SAD) study: Initiated Phase 1 SAD study in Australia with initial results expected in 2nd half of 2024."

Orphan drug • P1 data • Dermatology • Genetic Disorders • Muscular Dystrophy • Rare Diseases

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases (GlobeNewswire) - "Almirall...and Eloxx Pharmaceuticals...announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases....The drug candidate is expected to shortly enter into Phase I development in healthy volunteers. As part of this agreement, Eloxx will receive an upfront of $3 million, and additional payments throughout the potential development phases, including regulatory and sales milestones of up to $470 million, as well as tiered royalties based on any potential future global sales."

Licensing / partnership • Dermatology